Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MedImmune has achieved the primary endpoint for its drug Numax in a phase III study for respiratory illness.
Subscribe to our email newsletter
Numax met its primary endpoint of non-inferiority by reducing the incidence of hospitalizations caused by respiratory syncytial virus (RSV) in infants at high risk by 26% when compared to the standard treatment Synagis.
The data also indicate that Numax showed superiority over Synagis in a secondary endpoint by reducing the incidence of RSV-specific medically attended outpatient lower respiratory infections by approximately 52%.
In this preliminary assessment, the number and type of adverse events and serious adverse events were balanced between the study groups.
“The preliminary results of this study are highly encouraging and indicate that Numax may have the potential to offer high-risk infants additional protection against RSV infection over and above Synagis, which has an established safety and efficacy profile,” said Edward Connor, chief medical officer.
MedImmune commented that it would continue to analyze the phase III data.